Polycythemia Vera is the Primary Blood Malignancy Associated with Elevated RBC, Hematocrit, and Hemoglobin
Polycythemia vera (PV) is the principal hematologic malignancy characterized by erythrocytosis (elevated hemoglobin >16.5 g/dL in men, >16.0 g/dL in women, or hematocrit >49% in men, >48% in women). 1 This is a JAK2-driven myeloproliferative neoplasm that affects approximately 65,000 people in the US with an annual incidence of 0.5-4.0 cases per 100,000 persons. 2
Diagnostic Criteria for Polycythemia Vera
According to the 2016 WHO criteria endorsed by the European LeukemiaNet, PV diagnosis requires:
Major Criteria:
- Elevated hemoglobin (>16.5 g/dL men, >16.0 g/dL women) or hematocrit (>49% men, >48% women) 1
- Bone marrow biopsy showing age-adjusted hypercellularity with trilineage myeloproliferation 1
- Presence of JAK2 mutation (found in >95% of PV cases) 1, 2
Minor Criterion:
- Subnormal serum erythropoietin level 1
Diagnosis requires either all three major criteria OR the first two major criteria plus the minor criterion. 1
Other Myeloproliferative Neoplasms with Potential Erythrocytosis
While PV is the primary malignancy, two other Philadelphia chromosome-negative myeloproliferative neoplasms can occasionally present with elevated blood counts:
Essential Thrombocythemia (ET)
- Primarily presents with thrombocytosis (≥450 × 10⁹/L), not erythrocytosis 1
- JAK2, CALR, or MPL mutations present in 50% of cases 1
- Does NOT meet criteria for elevated hemoglobin/hematocrit that defines PV
Primary Myelofibrosis (PMF)
- Typically presents with anemia, NOT erythrocytosis 1
- Characterized by bone marrow fibrosis and megakaryocyte proliferation
- JAK2, CALR, or MPL mutations present in approximately 50% of cases 1
Critical Distinguishing Features
The JAK2V617F mutation is the key molecular marker: It is present in >95% of PV cases but only ~50% of ET and PMF cases. 1, 2 This mutation, combined with erythrocytosis, essentially confirms PV rather than other myeloproliferative neoplasms.
Erythropoietin levels differentiate primary from secondary causes: PV shows subnormal erythropoietin levels, while secondary erythrocytosis (from hypoxia, sleep apnea, smoking, testosterone use) shows normal or elevated levels. 3, 4
Clinical Significance and Complications
PV carries significant morbidity and mortality risks:
- Thrombotic events: 16% arterial thrombosis and 7% venous thrombosis at or before diagnosis 2
- Transformation risk: 12.7% develop myelofibrosis and 6.8% develop acute myeloid leukemia 2
- Median survival: 14.1 to 27.6 years from diagnosis 2
Common Pitfall to Avoid
Do not confuse relative polycythemia (plasma volume contraction) or secondary erythrocytosis with malignancy. 5 The presence of isolated erythrocytosis without leukocytosis or thrombocytosis should prompt investigation for secondary causes (hypoxia, sleep apnea, smoking, erythropoietin-secreting tumors, SGLT2 inhibitors, androgens) before assuming malignancy. 6, 5 However, when erythrocytosis occurs with leukocytosis (49% of PV cases) or thrombocytosis (53% of PV cases), immediately test for JAK2 mutations and serum erythropoietin levels. 2, 5